Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Satsuma Pharmaceuticals

Request full access

Developing best-in-class products to address the unmet needs of migraine sufferers

San Francisco, United StatesFounded 2016Biotech & Life Sciences

About Satsuma Pharmaceuticals

Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative treatments for migraine sufferers. The company operates primarily in the healthcare and pharmaceutical sectors, targeting individuals who experience acute migraine attacks. Satsuma's flagship product, STS101, is a novel investigational drug-device combination designed for intranasal administration of dihydroergotamine mesylate (DHE). This product aims to provide a reliable and effective treatment option for migraines, especially for patients whose conditions are nonresponsive to existing therapies like triptans.

Satsuma's business model revolves around the research, development, and eventual commercialization of STS101. The company generates revenue through clinical trials, partnerships, and potential future sales of its proprietary drug. By leveraging advanced nasal drug delivery systems and engineered drug particle technologies, Satsuma aims to offer a differentiated therapeutic option that could significantly reduce healthcare costs associated with migraine-related productivity losses.

The company serves a niche market of migraine sufferers, estimated to contribute to $36 billion annually in lost productivity in the U.S. alone. With operations based in South San Francisco, CA, and Research Triangle Park, NC, Satsuma is well-positioned to advance its clinical trials and bring STS101 to market upon regulatory approval.

Source: Dealroom company data

At a glance

Founded
2016
Headquarters
San Francisco, United States
Sector
Biotech & Life Sciences

Satsuma Pharmaceuticals in the San Francisco ecosystem

Live from Dealroom

The Satsuma Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

8 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A8 investors entered at this stage

Team profiled 6 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
2 countries with
team presence
🇺🇸 United States85.7%
🇲🇦 Morocco4.8%
2 countries shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Satsuma Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Satsuma Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.